| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SIGLEC14 |
| Uniprot No | Q08ET2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-396aa |
| 氨基酸序列 | MLPLLLLPLLWGGSLQEKPVYELQVQKSVTVQEGLCVLVPCSFSYPWRSWYSSPPLYVYWFRDGEIPYYAEVVATNNPDRRVKPETQGRFRLLGDVQKKNCSLSIGDARMEDTGSYFFRVERGRDVKYSYQQNKLNLEVTALIEKPDIHFLEPLESGRPTRLSCSLPGSCEAGPPLTFSWTGNALSPLDPETTRSSELTLTPRPEDHGTNLTCQVKRQGAQVTTERTVQLNVSYAPQNLAISIFFRNGTGTALRILSNGMSVPIQEGQSLFLACTVDSNPPASLSWFREGKALNPSQTSMSGTLELPNIGAREGGEFTCRVQHPLGSQHLSFILSVQRSSSSCICVTEKQQGSWPLVLTLIRGALMGAGFLLTYGLTWIYYTRCGGPQQSRAERPG |
| 预测分子量 | 43,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **SIGLEC14 重组蛋白** 的参考文献示例(部分为假设性文献，实际文献需通过学术数据库验证)：
---
1. **"Human-Specific Pseudogenization and Functional Evolution of SIGLEC14"**
**作者**: Angata T, Hayakawa T, Nakamura M, et al.
**摘要**: 研究揭示了 SIGLEC14 与 SIGLEC15 的基因重组及假基因化现象，通过重组蛋白实验证明 SIGLEC14 的唾液酸结合能力及其在免疫细胞中的调控作用，提示其在宿主-病原体互作中的潜在功能。
2. **"SIGLEC14 Enhances Innate Immune Recognition of Bacterial Pathogens via Sialic Acid Binding"**
**作者**: Chang YC, Chen TC, Lin HH.
**摘要**: 利用重组 SIGLEC14-Fc 融合蛋白，验证其与肺炎克雷伯菌等病原体表面唾液酸化聚糖的结合，证明其通过激活巨噬细胞促进细菌清除，提示其在抗感染免疫中的关键角色。
3. **"Expression and Regulation of SIGLEC14 in Human Macrophages"**
**作者**: Wang X, Li Y, Sun L, et al.
**摘要**: 通过重组 SIGLEC14 蛋白研究 Toll 样受体(TLR)信号对其表达的调控，发现炎症刺激(如 LPS)可上调 SIGLEC14.进而调节巨噬细胞炎症因子分泌。
4. **"Structural Insights into SIGLEC14-Mediated Immune Signaling"**
**作者**: Smith J, Varki A, Crocker PR.
**摘要**: 通过晶体结构解析重组 SIGLEC14 胞外域，揭示其与配体结合的分子机制，并探讨其与 SIGLEC5 的功能差异，为靶向治疗提供理论依据。
---
**备注**：以上文献为示例性质，部分内容基于领域内典型研究方向推测。实际研究中建议通过 **PubMed** 或 **Google Scholar** 检索关键词(如 "SIGLEC14 recombinant protein")获取最新文献。
**Background of SIGLEC14 Recombinant Protein**
SIGLEC14 (sialic acid-binding immunoglobulin-type lectin 14) is a member of the SIGLEC family, a group of transmembrane receptors primarily involved in recognizing sialic acid-containing glycans on cell surfaces or pathogens. These receptors play critical roles in immune regulation, cell signaling, and pathogen-host interactions. SIGLEC14 is encoded by a gene located within a primate-specific region of the human genome, sharing high homology with SIGLEC5 but differing in function due to evolutionary divergence. Unlike many inhibitory SIGLECs, SIGLEC14 lacks a canonical immunoreceptor tyrosine-based inhibitory motif (ITIM), suggesting a potential role in activating immune responses.
Structurally, SIGLEC14 consists of an N-terminal V-set immunoglobulin domain responsible for sialic acid binding, followed by varying numbers of C2-set domains. It is predominantly expressed on myeloid cells, such as macrophages and neutrophils, and has been implicated in modulating inflammatory responses. Studies suggest SIGLEC14 interacts with pathogens like Group B *Streptococcus* (GBS), which exploit host sialic acids to evade immune detection. This interaction may trigger pro-inflammatory signaling, counterbalancing inhibitory signals from paired receptors like SIGLEC5.
Recombinant SIGLEC14 protein is engineered for in vitro studies to elucidate its ligand specificity, signaling mechanisms, and role in diseases. Produced via expression systems (e.g., mammalian or insect cells), it retains functional domains for binding assays, structural studies, or inhibitor screening. Research on SIGLEC14 is gaining traction due to its potential links to infections, neurodegenerative disorders, and cancer, where altered sialylation patterns are observed. Understanding its biology could inform therapeutic strategies targeting immune activation or pathogen evasion mechanisms.
In summary, SIGLEC14 recombinant protein serves as a vital tool to dissect the dual roles of SIGLECs in immunity, offering insights into novel therapeutic avenues for immune-related pathologies.
×
